drugset
drugset / Trial / NCT05765734

A Study of TAS3351 in NSCLC Patients With EGFRmt

NCT05765734 ↗

Phase 1 Terminated 18 enrolled Taiho Oncology, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a first-in-human, open label, Phase 1/2 study to investigate the safety and efficacy of TAS3351 in participants with advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.

Timeline

Start
2023-05-25
Primary completion
2025-03-14
Completion
2025-03-14

Outcome

Outcome not reported

Stopped: “Sponsor's decision, not based on safety concerns”

Drugs

EvaluationDrugModalityDoseRoute
Subject TAS3351 Unknown 50 mg Oral
Subject TAS3351 Unknown 100 mg Oral
Subject TAS3351 Unknown 200 mg Oral
Subject TAS3351 Unknown 350 mg Oral
Subject TAS3351 Unknown 500 mg Oral
Subject TAS3351 Unknown 700 mg Oral

Indications

non-small cell lung carcinoma